查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1993199

急性肺損傷治療市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、病患年齡層、治療環境、最終用戶和通路分類）

Acute Lung Injury Treatment Market by Drug Class, Administration Route, Patient Age Group, Treatment Setting, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，急性肺損傷治療市場價值將達到 33.6 億美元，到 2026 年將成長至 35.2 億美元，到 2032 年將達到 45.2 億美元，複合年成長率為 4.30%。

主要市場統計數據
基準年 2025 33.6億美元
預計年份：2026年 35.2億美元
預測年份：2032年 45.2億美元
複合年成長率 (%) 4.30%

此綜合框架概述了急性肺損傷的臨床挑戰和治療重點，指導相關人員採用實證治療和交付管道。

急性肺損傷仍然是重症監護和急診醫學領域的核心臨床挑戰，需要大力改進治療方法、最佳化診療路徑，並將不斷更新的實證醫學證據融入臨床實踐。本導言概述了目前的研究現狀，整合了人工呼吸器相關併發症、控制發炎、改善肺泡功能以及抑制常與嚴重呼吸衰竭相關的器官衰竭鏈。此外，本導言還將治療分類、給藥途徑、護理環境和配送系統置於一個切實可行的決策框架中，旨在為臨床醫生、醫院管理者、保險公司和生命科學領域的高階主管提供參考。

臨床實務的進步、醫療服務的演變以及配送的現代化，是如何重塑醫院急性肺損傷治療的開發和實施的？

急性肺損傷的治療格局正在經歷一場變革，這主要得益於藥物研發的進步、臨床指南的不斷完善以及高危急症治療環境下醫療服務模式的轉變。對發炎路徑和肺泡修復機制的新認知正在重新評估現有藥物的合理性，促使人們重新審視皮質類固醇的給藥策略，並重新燃起對具有肺功能調節作用的輔助藥物的興趣。同時，通氣策略和鎮靜通訊協定的改進正在影響床邊藥物治療的實施方式，為那些與現代呼吸照護通訊協定具有協同作用的治療方法創造了機會。

本研究評估了關稅壓力對供應鏈的影響如何推動急性肺損傷治療領域的多元化、近岸外包和供應連續性策略。

關稅的實施使得用於治療急性肺損傷的藥品原料和製劑的供應鏈設計、製造地選擇和籌資策略備受關注。先前依賴地域集中型生產體系的企業正在重新評估其供應商多元化策略，以降低關稅風險並應對複雜的海關手續。對許多相關人員，這促使他們重新關注近岸外包方案、活性成分（API）的雙重採購策略以及能夠應對跨境成本波動的合約條款。

將藥物類別、給藥途徑、醫療保健環境和分銷管道與臨床應用和營運績效聯繫起來的詳細細分分析。

細分市場分析揭示了不同藥物類別、給藥途徑、終端用戶群體、分銷管道、患者年齡層和治療環境的需求促進因素和營運考慮因素各不相同。在各類藥物中，皮質類固醇類藥物，尤其是地塞米松、Hydrocortisone和Methylprednisolone等藥物的抗發炎特性，已引起策略性關注。同時，順式阿曲氯銨、羅庫溴銨和維庫溴銨等神經肌肉阻斷劑仍是促進肺部保護性通氣的重要工具。肺表面活性物質療法，例如貝拉坦和聚乳酸，在調節肺泡表面張力可帶來臨床益處的特定臨床場景中仍然至關重要。此外，吸入性血管擴張劑（例如一氧化氮）可用作輔助性治療，以改善難治性低氧血症患者的氧合。

對影響全球急性肺損傷治療普及的醫療服務模式、監管趨勢和供應鏈進行區域比較分析。

區域趨勢正在影響全球關鍵地區急性肺損傷治療的臨床實踐模式、監管合作和商業性模式。在美洲，整合的醫院網路和先進的三級醫療體系推動了對強調快速轉入加護病房（ICU）管理的通訊協定的需求，這些方案需要先進的機械通氣技術和完善的ICU藥房基礎設施的支持。這些特點能夠與複雜的診療路徑無縫銜接，並支持涉及醫院藥房委員會和重症監護學會等相關人員相關者的治療方法。

公司的策略重點是加強急性肺損傷治療的交付，並專注於臨床證據、生產韌性和夥伴關係模式。

企業層面的發展趨勢體現在對合作夥伴關係的策略性投資上，這些投資旨在加速臨床開發、提升生產韌性並加快臨床應用，同時增強供應的連續性。領先的製藥研發公司優先考慮提供證據，證明其產品與現代呼吸器和鎮靜通訊協定的兼容性，同時投資於製劑創新和包裝，以實現在急診環境中的快速給藥。製造商與合約研發生產機構（CDMO）之間的策略合作日益普遍，旨在提高生產規模的柔軟性並支持生產的地理多元化。

製造商和醫療保健領導者利用可操作的策略挑戰來加強臨床導入、供應鏈韌性和綜合護理路徑。

業界領導者應優先考慮一系列切實可行的舉措，以提升急性肺損傷治療的臨床療效、供應穩定性和商業性效益。首先，臨床開發和上市後證據項目必須與現代重症監護實踐相契合，透過設計能夠反映當前機械通氣策略、常見合併症以及對臨床醫生和醫院藥房委員會至關重要的可操作終點的研究。這樣做將有助於各機構縮小監管核准與實際效用之間的證據差距，從而支持更快的推廣應用和最佳化治療路徑。

結合證據整合、相關人員訪談和供應鏈分析的穩健混合方法研究途徑，可提供臨床適用的見解。

本分析的調查方法結合了系統性的證據整合、與關鍵相關人員的溝通以及嚴格的資料交叉檢驗，以確保其可靠性和有效性。此方法首先對同行評審的臨床文獻、監管核准、附加檔資訊進行全面審查，從而建立相關治療領域的臨床證據和安全性基礎。其次，透過與重症監護醫師、醫院藥劑師和採購經理進行結構化訪談，補充上述依證，以深入了解通訊協定選擇標準、操作限制和實施障礙等方面的實際問題。

整合臨床、營運和供應鏈要求，這些要求必須協調一致，才能將治療方面的進步與患者療效的可衡量改善聯繫起來。

總之，推動急性肺損傷的治療需要各方面協調一致：包括臨床證據的累積、實際操作的落實以及供應鏈的韌性。皮質類固醇、神經肌肉阻斷劑、界面活性劑和血管擴張劑等療法在現代治療模式中均發揮重要作用，而其有效實施取決於給藥途徑、護理環境和配送模式是否符合急性護理的實際情況。此外，還需要採取積極主動的籌資策略和以本地為本的方法，以應對價格管制和區域監管差異造成的供應脆弱性，確保患者能夠不間斷地獲得治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：急性肺損傷治療市場：依藥物類別分類

  • 皮質類固醇
    • 地塞米松
    • Hydrocortisone
    • Methylprednisolone
  • 神經肌肉阻斷劑
    • 西斯托拉庫里姆
    • 羅庫溴銨
    • 維庫溴銨
  • 界面活性劑
    • 棘棘魚
    • 乳酸菌 α
  • 血管擴張劑

第9章：急性肺損傷治療市場：依給藥途徑分類

  • 吸入
  • 靜脈

第10章：急性肺損傷治療市場：依患者年齡層別分類

  • 成人
  • 老年人
  • 兒童

第11章 急性肺損傷治療市場：依治療場所分類

  • 急診室
  • 普通病房
  • 加護病房

第12章：急性肺損傷治療市場：依最終用戶分類

  • 門診部
  • 醫院
  • 研究機構

第13章：急性肺損傷治療市場：依通路分類

  • 醫院藥房
    • 住院藥房
    • 門診藥房
  • 網路藥房
    • 直接向患者銷售
    • 第三方配藥
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第14章 急性肺損傷治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：急性肺損傷治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 急性肺損傷治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國急性肺損傷治療市場

第18章：中國急性肺損傷治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca PLC
  • Bayer AG
  • BioLineRx Ltd.
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici SpA
  • CSL Behring LLC.
  • Eli Lilly and Company
  • FibroGen, Inc.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Ltd.
  • Lisata Therapeutics, Inc.
  • Merck & Co., Inc.
  • Mesoblast Limited
  • Novartis International AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Synairgen plc
  • Takeda Pharmaceutical Company Limited
  • Windtree Therapeutics, Inc.
Product Code: MRR-1A1A064C0344

The Acute Lung Injury Treatment Market was valued at USD 3.36 billion in 2025 and is projected to grow to USD 3.52 billion in 2026, with a CAGR of 4.30%, reaching USD 4.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.36 billion
Estimated Year [2026] USD 3.52 billion
Forecast Year [2032] USD 4.52 billion
CAGR (%) 4.30%

Comprehensive framing of acute lung injury clinical challenges and therapeutic priorities to orient stakeholders toward evidence-based treatment and delivery pathways

Acute lung injury remains a central clinical challenge across critical care and emergency medicine, prompting intensive efforts to refine therapeutic approaches, optimize care pathways, and integrate evolving evidence into practice. This introduction frames the landscape by synthesizing the prevailing clinical imperatives: reducing ventilator-associated injury, managing inflammation, enhancing alveolar function, and attenuating the cascade of organ dysfunction that often accompanies severe respiratory compromise. It situates therapeutic classes, administration routes, care settings, and distribution frameworks within a practical decision-making context that speaks directly to clinicians, hospital leaders, payers, and life sciences executives.

Transitioning from clinical priorities to system-level implications, this section underscores how multidisciplinary coordination, supply chain resilience, and regulatory clarity are shaping implementation timelines for novel and repurposed interventions. It highlights the need for integrated protocols that reconcile pharmacologic strategies with ventilatory management and supportive care, while also calling attention to the crucial role of real-world evidence and clinician preference in driving adoption. The introduction sets expectations for the remainder of the report by outlining the analytical lens applied throughout: a synthesis of clinical evidence, regulatory signals, stakeholder interviews, and distribution dynamics intended to support informed strategic choices.

How converging clinical advances, care delivery evolution, and distribution modernization are reshaping acute lung injury therapeutic development and hospital adoption

The therapeutic landscape for acute lung injury is undergoing transformative shifts driven by advances in drug development, evolving clinical guidelines, and changes in care delivery models within high-acuity environments. Novel insights into the inflammatory pathways and alveolar repair mechanisms are reshaping the rationale for existing drug classes, prompting reconsideration of corticosteroid dosing strategies and renewed interest in adjunctive agents that modulate pulmonary mechanics. Concurrently, precision in ventilation strategies and sedation protocols is influencing how pharmacologic interventions are deployed at the bedside, creating opportunities for therapies that demonstrate synergy with contemporary respiratory care protocols.

In parallel, the commercialization and distribution environment is adapting to digital enablement, inventory optimization, and heightened scrutiny of supply continuity. These forces drive greater collaboration between manufacturers, hospital pharmacies, and specialty distributors, while also elevating the importance of value demonstration and post-market evidence generation. Regulatory pathways are increasingly emphasizing robust safety monitoring and real-world performance data, which in turn informs payer and hospital procurement expectations. Together, these dynamics are producing a landscape that rewards integrated evidence generation, nimble manufacturing practices, and clinically meaningful differentiation across treatment modalities.

Assessing how tariff-driven supply chain pressures are prompting diversification, nearshoring, and supply continuity strategies for acute lung injury therapeutics

The imposition of tariffs has heightened attention on supply chain design, manufacturing footprint decisions, and sourcing strategies for pharmaceutical inputs and finished formulations used in acute lung injury treatment. Companies that historically relied on geographically concentrated manufacturing are reassessing supplier diversification to mitigate tariff exposure and customs complexity. For many stakeholders, this has translated into a renewed emphasis on nearshoring options, dual-sourced active pharmaceutical ingredient (API) strategies, and contractual clauses that anticipate cross-border cost volatility.

Operational responses have included increased inventory buffers at hospital pharmacies coupled with closer collaboration between procurement teams and manufacturers to stabilize lead times and ensure continuity of care. Regulatory and quality oversight remain central to any sourcing shift, so firms pursuing alternative manufacturing arrangements prioritize established regulatory credentials and transparent audit trails. From a clinical perspective, continuity of access to established agents such as corticosteroids and neuromuscular blocking agents has been paramount, prompting contingency planning that aligns therapeutic protocols with available product formats and validated interchangeability strategies. Collectively, these adaptations underscore the importance of resilient supply networks and proactive stakeholder engagement in preserving treatment pathways amid tariff-driven disruptions.

In-depth segmentation insights linking drug classes, administration routes, care settings, and distribution channels to clinical application and operational execution

Segmentation analysis reveals differentiated demand drivers and operational considerations across drug classes, routes of administration, end-user profiles, distribution channels, patient age groups, and treatment settings. Across drug classes, corticosteroids command strategic attention with specific focus on agents such as dexamethasone, hydrocortisone, and methylprednisolone for their anti-inflammatory profiles, while neuromuscular blocking agents including cisatracurium, rocuronium, and vecuronium remain essential tools to facilitate lung-protective ventilation. Surfactant therapy, represented by agents like beractant and poractant alfa, continues to be critical in selected clinical scenarios where alveolar surface tension modulation offers clinical benefit, and inhaled vasodilators such as nitric oxide are deployed as adjuncts to improve oxygenation in refractory hypoxemia.

Route of administration drives logistical and clinical choices, with inhalation and intravenous options each presenting unique efficacy, onset, and safety trade-offs that inform protocol selection in the emergency department, general ward, or intensive care unit. End-user segmentation differentiates ambulatory care centers, hospitals, and research institutes by their clinical throughput, procedural capabilities, and research priorities, which in turn shapes expectations around product formats and support services. Distribution channel dynamics span hospital pharmacies, online pharmacies, and retail pharmacies; within hospital pharmacy operations, inpatient and outpatient pharmacy divisions have distinct inventory and dispensing workflows, while online channels include direct-to-patient and third-party fulfillment models that require careful cold-chain and regulatory compliance planning. Chain and independent retail pharmacies also play roles in outpatient transitions of care and patient access programs. Patient age group segmentation into adult, geriatric, and pediatric cohorts highlights dosing, safety, and formulation considerations that influence clinical decision-making and packaging design. Lastly, treatment setting segmentation across emergency departments, general wards, and intensive care units affects time-to-therapy imperatives, monitoring requirements, and interdisciplinary coordination needs, making alignment between therapeutic attributes and care environment essential for successful implementation.

Comparative regional analysis of care delivery models, regulatory dynamics, and supply chain considerations shaping acute lung injury treatment adoption globally

Regional dynamics shape clinical practice patterns, regulatory interactions, and commercial approaches for acute lung injury therapeutics across major global corridors. In the Americas, integrated hospital networks and a high degree of tertiary care capacity drive demand for protocols that emphasize rapid escalation to intensive care unit management, supported by advanced ventilatory technologies and established ICU pharmacy infrastructures. These characteristics favor therapies that integrate seamlessly with complex care pathways and where stakeholder engagement includes hospital formulary committees and critical care societies.

Europe, the Middle East & Africa encompasses a heterogeneous set of health systems, regulatory frameworks, and procurement models, which necessitates tailored market access strategies that account for national reimbursement mechanisms and region-specific clinical guidelines. Variability in critical care capacity and supply chain infrastructure in parts of this region can influence prioritization of stable supply channels and simplified administration profiles. Asia-Pacific features a mix of high-capacity urban tertiary centers and rapidly expanding regional care networks, with certain markets demonstrating accelerated adoption of digital health tools and tele-ICU models. In several parts of the region, manufacturing capacity and API production are significant factors that shape commercial negotiations and collaboration opportunities, and partnerships that address local clinical training and evidence generation often facilitate more rapid clinical integration. Across all regions, aligning regulatory strategy, evidence generation, and supply continuity plans with local clinical expectations remains central to successful implementation.

Strategic corporate priorities focusing on clinical evidence, manufacturing resilience, and partnership models to strengthen acute lung injury therapeutic delivery

Company-level dynamics are characterized by strategic investments in clinical development, manufacturing resilience, and collaborative partnerships that accelerate clinical adoption and strengthen supply continuity. Leading pharmaceutical developers are prioritizing evidence generation that demonstrates compatibility with contemporary ventilation and sedation protocols, while also investing in formulation innovations and packaging that facilitate rapid administration in acute care settings. Strategic alliances between manufacturers and contract development and manufacturing organizations are increasingly common to enhance scale flexibility and to support geographic diversification of production.

Commercially, companies are enhancing clinician engagement through targeted medical education, disease-state awareness initiatives, and real-world evidence programs that capture outcomes associated with varied treatment regimens. On the supply side, organizations are implementing advanced demand planning tools, serialized traceability, and quality-by-design practices to mitigate disruption risk and to satisfy heightened regulatory expectations. Additionally, some companies are expanding service offerings around patient support and hospital pharmacy integration to secure smoother transitions from acute care to outpatient follow-up. Collectively, these corporate strategies emphasize the integration of clinical relevance, operational robustness, and commercial agility to maintain continuity of care and to support evidence-informed decision-making across stakeholders.

Actionable strategic imperatives for manufacturers and healthcare leaders to strengthen clinical adoption, supply resilience, and integrated care pathways

Industry leaders should prioritize a set of pragmatic actions to enhance clinical impact, supply resilience, and commercial effectiveness for acute lung injury treatments. First, align clinical development and post-market evidence programs with contemporary critical care practice by designing studies that reflect modern ventilation strategies, common comorbidities, and pragmatic endpoints that matter to clinicians and hospital formulary committees. By doing so, organizations can reduce the evidence gap between regulatory approval and real-world clinical utility, supporting more rapid uptake and optimized care pathways.

Second, invest in diversified manufacturing and procurement strategies that balance cost efficiency with supply continuity, including dual sourcing of critical APIs, evaluation of nearshore production opportunities, and strengthened quality oversight across contract manufacturing partners. Third, deepen engagement with hospital pharmacy leaders, critical care clinicians, and procurement teams to co-design implementation protocols that address dosing convenience, storage constraints, and monitoring requirements across emergency departments, general wards, and intensive care units. Fourth, enhance digital and data infrastructure to capture real-world outcomes, support pharmacovigilance, and generate actionable insights for continuous improvement. Finally, develop flexible commercial models that consider hospital formulary dynamics and reimbursement environments, offering bundled service propositions and education programs that lower barriers to adoption while demonstrating clear operational benefits.

Robust mixed-methods research approach combining evidence synthesis, stakeholder interviews, and supply chain analysis to deliver clinically actionable insights

The research methodology underpinning this analysis combines systematic evidence synthesis, primary stakeholder engagement, and rigorous cross-validation of data to ensure reliability and relevance. The approach begins with comprehensive reviews of peer-reviewed clinical literature, regulatory approvals and labeling information, and publicly available clinical trial registries to establish a foundation of clinical evidence and safety profiles for the relevant therapeutic classes. This evidence base is then complemented by structured interviews with critical care clinicians, hospital pharmacy directors, and procurement leaders to surface practical insights about protocol preferences, operational constraints, and adoption barriers.

To capture distribution and operational dynamics, the methodology incorporates analysis of supply chain architectures, distribution channel practices, and regulatory compliance requirements, with particular attention to product formats and cold-chain considerations where relevant. Quality assurance steps include triangulation across multiple information sources, validation of key findings with subject matter experts, and sensitivity checks to ensure conclusions remain robust across divergent clinical and operational scenarios. Throughout, the research prioritizes transparency in data sources and methodological assumptions and emphasizes actionable interpretation to support decision-making by clinical, commercial, and operational stakeholders.

Synthesis of clinical, operational, and supply chain imperatives that must align to translate therapeutic advances into measurable improvements in patient outcomes

In conclusion, advancing the treatment of acute lung injury requires coordinated progress across clinical evidence generation, operational execution, and supply chain resilience. Therapeutic classes including corticosteroids, neuromuscular blocking agents, surfactants, and vasodilators each play defined roles within contemporary treatment paradigms, and their effective deployment depends on alignment with administration routes, care settings, and distribution models that meet the realities of acute care delivery. Addressing tariff-induced supply vulnerabilities and regional regulatory heterogeneity further necessitates proactive sourcing strategies and localized engagement to ensure uninterrupted patient access.

Moving forward, stakeholders who invest in pragmatic evidence generation, clinician-centered implementation design, and manufacturing flexibility will be best positioned to translate scientific advances into meaningful improvements in patient outcomes. Coordination across hospital systems, suppliers, and regulatory bodies remains essential to harmonize expectations and to streamline pathways from therapy availability to routine clinical use. Ultimately, the integration of rigorous clinical data, resilient operations, and collaborative stakeholder engagement will determine the trajectory of therapeutic impact for patients experiencing acute lung injury.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Lung Injury Treatment Market, by Drug Class

  • 8.1. Corticosteroids
    • 8.1.1. Dexamethasone
    • 8.1.2. Hydrocortisone
    • 8.1.3. Methylprednisolone
  • 8.2. Neuromuscular Blocking Agents
    • 8.2.1. Cisatracurium
    • 8.2.2. Rocuronium
    • 8.2.3. Vecuronium
  • 8.3. Surfactants
    • 8.3.1. Beractant
    • 8.3.2. Poractant Alfa
  • 8.4. Vasodilators

9. Acute Lung Injury Treatment Market, by Administration Route

  • 9.1. Inhalation
  • 9.2. Intravenous

10. Acute Lung Injury Treatment Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Acute Lung Injury Treatment Market, by Treatment Setting

  • 11.1. Emergency Department
  • 11.2. General Ward
  • 11.3. Intensive Care Unit

12. Acute Lung Injury Treatment Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Acute Lung Injury Treatment Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
    • 13.1.1. Inpatient Pharmacies
    • 13.1.2. Outpatient Pharmacies
  • 13.2. Online Pharmacies
    • 13.2.1. Direct To Patient
    • 13.2.2. Third Party Fulfillment
  • 13.3. Retail Pharmacies
    • 13.3.1. Chain Pharmacies
    • 13.3.2. Independent Pharmacies

14. Acute Lung Injury Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Acute Lung Injury Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Acute Lung Injury Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Acute Lung Injury Treatment Market

18. China Acute Lung Injury Treatment Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AstraZeneca PLC
  • 19.6. Bayer AG
  • 19.7. BioLineRx Ltd.
  • 19.8. Boehringer Ingelheim GmbH
  • 19.9. Chiesi Farmaceutici S.p.A.
  • 19.10. CSL Behring LLC.
  • 19.11. Eli Lilly and Company
  • 19.12. FibroGen, Inc.
  • 19.13. Genentech, Inc.
  • 19.14. Gilead Sciences, Inc.
  • 19.15. GlaxoSmithKline plc
  • 19.16. Hoffmann-La Roche Ltd.
  • 19.17. Lisata Therapeutics, Inc.
  • 19.18. Merck & Co., Inc.
  • 19.19. Mesoblast Limited
  • 19.20. Novartis International AG
  • 19.21. Pfizer Inc.
  • 19.22. Regeneron Pharmaceuticals, Inc.
  • 19.23. Sanofi S.A.
  • 19.24. Synairgen plc
  • 19.25. Takeda Pharmaceutical Company Limited
  • 19.26. Windtree Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 229. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 237. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 240. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 241. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 268. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 270. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 272. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 273. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 274. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 276. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 280. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 281. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 283. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 285. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 286. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 289. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 292. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 302. U